Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Nektar Therapeutics’s stock clocked out at $24.94, down -6.49% from its previous closing price of $26.67. In other words, the price has decreased by -$6.49 from its previous closing price. On the day, 1.1 million shares were traded. NKTR stock price reached its highest trading level at $27.7094 during the session, while it also had its lowest trading level at $24.51.
Ratios:
To gain a deeper understanding of NKTR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 13.59 whereas as Long-Term Debt/Eq ratio is at 12.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 24, 2025, Reiterated its Buy rating but revised its target price to $120 from $6.50 previously.
On June 24, 2025, BTIG Research reiterated its Buy rating and also lowered its target price recommendation from $60 to $100.
Jefferies Upgraded its Hold to Buy on April 11, 2025, while the target price for the stock was maintained at $2.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Zalevsky Jonathan sold 10,712 shares for $0.67 per share. The transaction valued at 7,177 led to the insider holds 305,892 shares of the business.
Wilson Mark Andrew sold 9,996 shares of NKTR for $6,697 on May 19 ’25. The Chief Legal Officer now owns 314,296 shares after completing the transaction at $0.67 per share. On May 19 ’25, another insider, ROBIN HOWARD W, who serves as the President & CEO of the company, sold 23,208 shares for $0.67 each. As a result, the insider received 15,549 and left with 1,063,693 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NKTR now has a Market Capitalization of 431474464 and an Enterprise Value of 288621600. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.95 while its Price-to-Book (P/B) ratio in mrq is 22.52. Its current Enterprise Value per Revenue stands at 3.308 whereas that against EBITDA is -2.113.
Stock Price History:
The Beta on a monthly basis for NKTR is 0.98, which has changed by 0.13881278 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, NKTR has reached a high of $37.38, while it has fallen to a 52-week low of $6.48. The 50-Day Moving Average of the stock is 61.57%, while the 200-Day Moving Average is calculated to be 69.27%.
Shares Statistics:
It appears that NKTR traded 1.76M shares on average per day over the past three months and 1247320 shares per day over the past ten days. A total of 17.30M shares are outstanding, with a floating share count of 16.86M. Insiders hold about 25.54% of the company’s shares, while institutions hold 58.19% stake in the company. Shares short for NKTR as of 1749772800 were 595786 with a Short Ratio of 0.69, compared to 1747267200 on 710759. Therefore, it implies a Short% of Shares Outstanding of 595786 and a Short% of Float of 4.95.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
